论文部分内容阅读
Objective Approximately 30-60%of acute B-lymphocytic leukemia(B-ALL)patients show refractory or relapse,which is one of the major causes of death in B-ALL patients,the methods on the treatment of relapsed/refractory B-ALL(R/R B-ALL)is limited.